CEL-SCI reports Multikine 5-year survival 82.6% in target head & neck cancer subgroup; HR 0.27

CEL SCI CORP

Multikine showed 82.6% 5-year overall survival in target low-risk patients vs 47.3% for standard of care.
73% reduction in risk of death (HR 0.27, 95% CI [0.12-0.64], Wald p=0.0027) in that subgroup.
Data presented at ESMO 2024 support confirmatory Registration Study (212 patients) with FDA go-ahead.
Target population: newly diagnosed locally advanced head & neck cancer, no lymph node involvement, low PD-L1.
Phase 3 study subset (n=79) deemed low risk for recurrence per NCCN guidelines, not recommended chemotherapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.